<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178814</url>
  </required_header>
  <id_info>
    <org_study_id>AAAF2696</org_study_id>
    <nct_id>NCT01178814</nct_id>
  </id_info>
  <brief_title>Revlimid in Transfusion Dependent Patients</brief_title>
  <official_title>A Prospective Trial of Revlimid® in Transfusion Dependent Patients With Non-del (5q) Low/Intermediate-1 Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective trial of Revlimid for subjects who have a blood cell cancer called&#xD;
      myelodysplastic syndrome (MDS). Cells in their marrow make proteins through messages that are&#xD;
      carried from the genes. The amount of the message tells researchers if the protein it is&#xD;
      going to make is high or low. This is known as expression of genes. The purpose of this study&#xD;
      is to conduct a prospective trial testing the idea that expression of specific genes can help&#xD;
      to predict which patients will respond to study drug administration with Revlimid&#xD;
      (lenalidomide).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first Revlimid® study reported by List et al included all transfusion dependent MDS&#xD;
      patients, but given the early experience which showed a better response in del(5q) patients&#xD;
      and those with lower risk disease, more patients belonging to this category were entered on&#xD;
      the trial. The subsequent multi-center studies were focused entirely on the low/Int-1&#xD;
      patients who were transfusion dependent. In the present study, we would like to recapitulate&#xD;
      the initial study by only treating the transfusion dependent, low and intermediate-1 risk MDS&#xD;
      patients without deletion (5q). Since the predictive assay is most applicable for the&#xD;
      non-del(5q) patients, and to avoid confusion resulting from an admixture of patients with&#xD;
      del(5q) for whom the drug is already FDA approved, we have elected to restrict this clinical&#xD;
      trial to only the non-del(5q) patients.&#xD;
&#xD;
      In the present study, only the non-del(5q) transfusion dependent, low and intermediate-1 risk&#xD;
      MDS patients will be treated with single agent Revlimid®. All patients will have their&#xD;
      pre-therapy bone marrows studied by gene expression microarray, Luminex bead assay, and&#xD;
      real-time PCR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Response Signature in Transfusion Dependent MDS Patients</measure>
    <time_frame>Up to 12 weeks from baseline</time_frame>
    <description>The trial will be testing the Revlimid® (lenalidomide) response signature in patients who have transfusion dependent, non-del(5q), low and intermediate-1 risk myelodysplastic syndromes (MDS) in order to confirm the predictive value of the signature and to establish the boundaries of the z-score which can be used to pre-select patients in future clinical studies.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Revlimid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revlimid (Lenalidomide) capsule taken orally once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revlimid (Lenalidomide)</intervention_name>
    <description>The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.</description>
    <arm_group_label>Revlimid</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent form.&#xD;
&#xD;
          -  Age ≥ 21 years at the time of signing the informed consent form.&#xD;
&#xD;
          -  Able to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          -  A confirmed diagnosis (using standard FAB criteria) of a myelodysplastic syndrome with&#xD;
             low/Int-1 risk and with a non-del(5q) karyotype must be established.&#xD;
&#xD;
          -  Patients must have transfusion dependence (at least 2 units within 8 weeks prior to&#xD;
             starting therapy).&#xD;
&#xD;
          -  All transfusion dependent non-del(5q) low/Int-1 risk patients will be eligible for&#xD;
             treatment with Revlimid®&#xD;
&#xD;
          -  Newly diagnosed as well as previously treated patients will be eligible&#xD;
&#xD;
          -  Patients with primary de novo or secondary MDS will be eligible&#xD;
&#xD;
          -  All previous cancer therapy, including radiation, hormonal therapy and surgery, must&#xD;
             have been discontinued at least 4 weeks prior to treatment in this study.&#xD;
&#xD;
          -  ECOG performance status of 0-2 at study entry (see Appendix II).&#xD;
&#xD;
          -  Laboratory test results within these ranges:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 250/uL&#xD;
&#xD;
               -  Platelet count &gt; 30,000/uL&#xD;
&#xD;
               -  Serum creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤ 3 x ULN&#xD;
&#xD;
               -  BUN ≤ 2 x ULN&#xD;
&#xD;
          -  Disease free of prior malignancies for ≥ 2 years with exception of currently treated&#xD;
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix&#xD;
             or breast.&#xD;
&#xD;
          -  All study participants must be registered into the mandatory RevAssist® program, and&#xD;
             be willing and able to comply with the requirements of RevAssist®.&#xD;
&#xD;
          -  Females of childbearing potential (FCBP)† must have a negative serum or urine&#xD;
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to&#xD;
             and again within 24 hours of prescribing lenalidomide (prescriptions must be filled&#xD;
             within 7 days) and must either commit to continued abstinence from heterosexual&#xD;
             intercourse or begin TWO acceptable methods of birth control, one highly effective&#xD;
             method and one additional effective method AT THE SAME TIME, at least 28 days before&#xD;
             she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men&#xD;
             must agree to use a latex condom during sexual contact with a FCBP even if they have&#xD;
             had a successful vasectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed&#xD;
             while taking lenalidomide).&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
          -  Any clinically significant cardiac disease, including congestive heart failure&#xD;
&#xD;
          -  Liver function studies including SGOT/SGPT &gt; 3 x ULN&#xD;
&#xD;
          -  Clinically significant renal disease.&#xD;
&#xD;
          -  Any previous chemotherapy, hematopoietic growth factors, erythropoietin, or cytokines&#xD;
             within 4 weeks of starting treatment. Note: prior therapy with G-CSF within 4 weeks is&#xD;
             allowed.&#xD;
&#xD;
          -  Use of any other experimental drug or therapy within 28 days of baseline.&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide.&#xD;
&#xD;
          -  The development of erythema nodosum if characterized by a desquamating rash while&#xD;
             taking thalidomide or similar drugs.&#xD;
&#xD;
          -  Any prior use of lenalidomide. (Patients with prior therapy with thalidomide will be&#xD;
             eligible as long as at least 4 weeks have elapsed between end of the drug and accrual&#xD;
             on the present trial)&#xD;
&#xD;
          -  Concurrent use of other anti-cancer agents or treatments.&#xD;
&#xD;
          -  Known positive for HIV or infectious hepatitis, type B or C.&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Heaney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <results_first_submitted>June 30, 2021</results_first_submitted>
  <results_first_submitted_qc>June 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2021</results_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 29, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01178814/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Revlimid</title>
          <description>Revlimid (Lenalidomide) capsule taken orally once a day&#xD;
Revlimid (Lenalidomide): The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Revlimid</title>
          <description>Revlimid (Lenalidomide) capsule taken orally once a day&#xD;
Revlimid (Lenalidomide): The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Response Signature in Transfusion Dependent MDS Patients</title>
        <description>The trial will be testing the Revlimid® (lenalidomide) response signature in patients who have transfusion dependent, non-del(5q), low and intermediate-1 risk myelodysplastic syndromes (MDS) in order to confirm the predictive value of the signature and to establish the boundaries of the z-score which can be used to pre-select patients in future clinical studies.</description>
        <time_frame>Up to 12 weeks from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revlimid</title>
            <description>Revlimid (Lenalidomide) capsule taken orally once a day&#xD;
Revlimid (Lenalidomide): The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Response Signature in Transfusion Dependent MDS Patients</title>
          <description>The trial will be testing the Revlimid® (lenalidomide) response signature in patients who have transfusion dependent, non-del(5q), low and intermediate-1 risk myelodysplastic syndromes (MDS) in order to confirm the predictive value of the signature and to establish the boundaries of the z-score which can be used to pre-select patients in future clinical studies.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Delayed response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Revlimid</title>
          <description>Revlimid (Lenalidomide) capsule taken orally once a day&#xD;
Revlimid (Lenalidomide): The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Heaney, MD</name_or_title>
      <organization>Columbia University Irving Medical Center</organization>
      <phone>646-317-5199</phone>
      <email>mlh2192@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

